Advanced colorectal carcinoma: redefining the role of oral ftorafur.

Abstract

The therapeutic performance, effect on quality of life and cost effectiveness of an orally administered medication in a home care setting were examined prospectively in a group of 61 patients presenting with advanced colorectal carcinoma. A regimen of daily ftorafur capsules (370 mg/m2) and leucovorin tablets (20 mg/m2) was offered to 35 symptomatic patients with poor performance status; the standard in-hospital i.v. protocol of 5-fluouracil and leucovorin was given to the remaining 26 patients. Follow-up and survival analysis indicated that there was no compromise in survival associated with home care and oral chemotherapy. There were statistically significant advantages in terms of reduced toxicity and improved Karnofsky performance status in this group. Home care was approximately 70% less expensive. A home treatment program based on oral ftorafur may be the most desirable option for all patients with advanced colorectal carcinoma.

• Authors: I G Ron, A Lotan, M J Inbar, S Chaitchik
• Journal: Anti-cancer drugs (Anticancer Drugs) Vol. 7 Issue 6 Pg. 649-54 (Aug 1996) ISSN: 0959-4973 [Print] England
• PMID: 8913433 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Antimetabolites, Antineoplastic
• Tegafur
• Leucovorin
• Fluorouracil

Topics

• Adenocarcinoma (drug therapy, economics)
• Adult
• Aged
• Aged, 80 and over
• Antimetabolites, Antineoplastic (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, economics, therapeutic use)
• Colorectal Neoplasms (drug therapy, economics)
• Female
• Fluorouracil (administration & dosage, economics)
• Home Nursing (economics)
• Humans
• Karnofsky Performance Status
• Leucovorin (administration & dosage, economics)
• Male
• Middle Aged
• Quality of Life
• Tegafur (administration & dosage, economics)